SCHEMBL1460744

SCHEMBL1460744

CC(=O)N(Cc1ccccc1)C1CCC(C(O)(C(F)(F)F)C(F)(F)F)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.48
DPP9 Q86TI2 1/20 0.48
DPP7 Q9UHL4 1/20 0.48
SLC6A2 P23975 2/20 0.44
SLC6A4 P31645 2/20 0.44
SLC6A3 Q01959 1/20 0.44
AGER Q15109 3/20 0.43
MTNR1A P48039 1/20 0.43
LMNA P02545 1/20 0.43
OPRM1 P35372 4/20 0.43
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP3 P08254 1/20 0.42
MMP7 P09237 1/20 0.42
MMP13 P45452 1/20 0.42
DCUN1D1 Q96GG9 3/20 0.41
CHRM2 P08172 1/20 0.41
CHRM3 P20309 1/20 0.41
KCNH2 Q12809 1/20 0.40
CRHBP P24387 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1460765 0.90 AGER (0.43) DPP4DPP9DPP7AGERMTNR1A
SCHEMBL1461928 0.88 OPRM1 (0.58) SLC6A2SLC6A4SLC6A3AGERMTNR1A
SCHEMBL1460997 0.86 OPRM1 (0.55) AGERMTNR1AOPRM1DCUN1D1KCNH2
SCHEMBL1461945 0.79 GRIN2B (0.48) DPP4DPP9DPP7SLC6A2SLC6A4
SCHEMBL1461003 0.78 SLC6A2 (0.41) SLC6A2SLC6A4SLC6A3LMNAOPRM1
SCHEMBL1460723 0.77 DRD2 (0.47) SLC6A2SLC6A4
SCHEMBL13503958 0.76 DPP4 (0.57) DPP4DPP9DPP7SLC6A2SLC6A4
SCHEMBL5355490 0.75 SLC6A2 (0.44) DPP4DPP9DPP7SLC6A2SLC6A4
SCHEMBL619150 0.75 SLC6A2 (0.71) DPP4DPP9DPP7SLC6A2SLC6A4
SCHEMBL1461010 0.75 ESR2 (0.51)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4644714-B2 2011-03-02 JP claimed
JP-2008524280-A 2008-07-10 JP claimed
EP-1831158-A1 NOVEL CYCLOHEXANE DERIVATIVES F. Hoffmann-Roche AG (CH) 2007-09-12 EP claimed
US-7253282-B2 Hexafluoroisopropanol substituted cyclohexane derivatives HOFFMAN-LA ROCHE INC. (US) 2007-08-07 US claimed
WO-2006066779-A1 NOVEL CYCLOHEXANE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-06-29 WO claimed
US-20060135601-A1 Novel hexafluoroisopropanol substituted cyclohexane derivatives HOFFMANN-LA ROCHE INC. 2006-06-22 US claimed
EP-1831158-A1 NOVEL CYCLOHEXANE DERIVATIVES F. Hoffmann-Roche AG (CH) 2007-09-12 EP disclosed
US-7253282-B2 Hexafluoroisopropanol substituted cyclohexane derivatives HOFFMAN-LA ROCHE INC. (US) 2007-08-07 US disclosed
WO-2006066779-A1 NOVEL CYCLOHEXANE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2006-06-29 WO disclosed
US-20060135601-A1 Novel hexafluoroisopropanol substituted cyclohexane derivatives HOFFMANN-LA ROCHE INC. 2006-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060135601-A1 Novel hexafluoroisopropanol substituted cyclohexane derivatives NR1H3, NR1H2, NR1I2 DPP4 2019/4885DPP9 3205/4885DPP7 3173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.